{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Collect predose urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform predose 12-lead ECG.', 'Perform predose physical and ophthalmic examinations, including vital signs. Additional', 'vital sign monitoring may be performed in the event of infusion-associated AEs (see', 'Section 9.5.4.3 for details).', 'Measure weight.', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', 'Administer predose GO-QoL questionnaire.', 'Obtain study medication vial assignment and volume of study drug to be administered', 'from EDC.', 'Administer study drug and record date, volume and rate of infusion, and start/stop times', 'of dosing.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic at Week 15.', '9.5.6.8 Week 15', 'Obtain predose blood samples for hematology and glucose analysis (see Section 9.5.4.6', 'for details concerning test results and study participation).', 'Perform predose urine pregnancy test for females of childbearing potential; the', 'pregnancy test must be negative for the subject to receive study drug.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Collect predose vital signs. Additional vital sign monitoring may be performed in the', 'event of infusion-associated AEs (see Section 9.5.4.3 for details).', 'Obtain study medication vial assignment and volume of study drug to be administered', 'from EDC.', 'Administer study drug and record date, volume and rate of infusion, and start/stop times', 'of dosing.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 99 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic at Week 18.', '9.5.6.9 Week 18', 'Obtain predose blood samples for hematology and chemistry (including thyroid, glucose,', 'but not HbA1c) analysis (see Section 9.5.4.6 for details concerning test results and study', 'participation).', 'Collect predose urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform predose physical and ophthalmic examinations, including vital signs. Additional', 'vital sign monitoring may be performed in the event of infusion-associated AEs (see', 'Section 9.5.4.3 for details).', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', 'Obtain study medication vial assignment and volume of study drug to be administered', 'from EDC.', 'Administer study drug and record date, volume and rate of infusion, and start/stop times', 'of dosing.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic at Week 21.', '9.5.6.10 Week 21', 'Obtain predose blood samples for hematology and glucose analysis (see Section 9.5.4.6', 'for details concerning test results and study participation).', 'Collect predose urine sample for a pregnancy test for females of childbearing potential.', 'The pregnancy test must be negative for those subjects to receive study drug.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Collect predose vital signs. Additional vital sign monitoring may be performed in the', 'event of infusion-associated AEs (see Section 9.5.4.3 for details).', 'Obtain study medication vial assignment and volume of study drug to be administered', 'from EDC.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 100 of 118']\n\n###\n\n", "completion": "END"}